1-16 of 16
Ramón Salazar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B038: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study

Valentino Martelli, Joana Vidal, Maria Concepción Fernández-Rodríguez, Pilar García-Alfonso, David Páez, Joan Gibert, Jennifer Linares, Annarita Sibilio, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Duran, Elena Élez, José Luis Manzano, Rocio Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Auxiliadora Gomez-España, Rodrigo Toledo, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Ramon Ramon Salazar, Enrique Aranda, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B038.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B038
Published: 13 November 2024
View article titled, Abstract B038: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study
Journal Articles

Abstract PR009: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study

Valentino Martelli, Joana Vidal, Maria Concepción Fernández-Rodríguez, Pilar García-Alfonso, David Páez, Joan Gibert, Jennifer Linares, Annarita Sibilio, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Duran, Elena Élez, José Luis Manzano, Rocio Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Auxiliadora Gomez-España, Rodrigo Toledo, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Ramon Ramon Salazar, Enrique Aranda, Clara Montagut
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): PR009.
https://doi.org/10.1158/1557-3265.LIQBIOP24-PR009
Published: 13 November 2024
View article titled, Abstract PR009: Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: Findings from the PLATFORM-B study
Journal Articles

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, Pilar García-Alfonso, David Páez, Marta Guix, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Durán, Elena Elez, José Luís Manzano, Rocío Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Enrique Aranda, Ramon Salazar, Clara Montagut, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 379–388.
https://doi.org/10.1158/1078-0432.CCR-22-1696
Published: 17 January 2023
View article titled, Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Open the PDF for Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study in another window
Includes: Supplementary data
Journal Articles

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

Laetitia Marisa, Yuna Blum, Julien Taieb, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramon Salazar, Daniela Aust, Alex Duval, Hélène Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Selves, Sophie Mouillet-Richard, Valérie Boige, Jean-François Emile, Aurélien de Reyniès, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4768–4780.
https://doi.org/10.1158/1078-0432.CCR-21-0529
Published: 01 September 2021
View article titled, Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Open the PDF for Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

Gino M. Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C. T. Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Josep Tabernero, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Andrea Marrari, M. Carmen Carmona-García, Neha Chopra, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia A. Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Lorenza Scotti, Alvin J. X. Lee, Thomas Newsom-Davis, Andrea Patriarca, Lorenza Rimassa, Armando Santoro, Alessandra Gennari, Mieke Van Hemelrijck, Nikolaos Diamantis, David J. Pinato
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): S01-03.
https://doi.org/10.1158/1557-3265.COVID-19-21-S01-03
Published: 15 March 2021
View article titled, Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score
Journal Articles

Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer

Natalia Guillén Díaz-Maroto, Rebeca Sanz-Pamplona, Mireia Berdiel-Acer, Francisco J. Cimas, Elena García, Samuel Gonçalves-Ribeiro, Nerea Albert, Gemma Garcia-Vicién, Gabriel Capella, Victor Moreno, Ramon Salazar, Alberto Villanueva, David G. Molleví
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4466–4479.
https://doi.org/10.1158/1078-0432.CCR-18-3957
Published: 15 July 2019
View article titled, Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Open the PDF for Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Optimizing Anti-EGFR Therapy in Colorectal Cancer

Ramon Salazar, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5415–5416.
https://doi.org/10.1158/1078-0432.CCR-15-1768
Published: 14 December 2015
View article titled, Optimizing Anti-EGFR Therapy in Colorectal Cancer
Open the PDF for Optimizing Anti-EGFR Therapy in Colorectal Cancer in another window
Journal Articles

Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer

Rebeca Sanz-Pamplona, Adriana Lopez-Doriga, Laia Paré-Brunet, Kira Lázaro, Fernando Bellido, M. Henar Alonso, Susanna Aussó, Elisabet Guinó, Sergi Beltrán, Francesc Castro-Giner, Marta Gut, Xavier Sanjuan, Adria Closa, David Cordero, Francisco D. Morón-Duran, Antonio Soriano, Ramón Salazar, Laura Valle, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4709–4718.
https://doi.org/10.1158/1078-0432.CCR-15-0159
Published: 14 October 2015
View article titled, Exome Sequencing Reveals <em>AMER1</em> as a Frequently Mutated Gene in Colorectal Cancer
Open the PDF for Exome Sequencing Reveals <em>AMER1</em> as a Frequently Mutated Gene in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade?

Ramon Salazar, Gabriel Capellà, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6227–6229.
https://doi.org/10.1158/1078-0432.CCR-14-1615
Published: 14 December 2014
View article titled, Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade?
Open the PDF for Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade? in another window
Journal Articles

New Approaches but the Same Flaws in the Search for Prognostic Signatures

Ramon Salazar, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2019–2022.
https://doi.org/10.1158/1078-0432.CCR-14-0219
Published: 15 April 2014
View article titled, New Approaches but the Same Flaws in the Search for Prognostic Signatures
Open the PDF for New Approaches but the Same Flaws in the Search for Prognostic Signatures in another window
Journal Articles

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2541–2550.
https://doi.org/10.1158/1078-0432.CCR-13-0107
Published: 30 April 2013
View article titled, Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Open the PDF for Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial in another window
Includes: Supplementary data
Journal Articles

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

August Vidal, Clara Muñoz, María-José Guillén, Jemina Moretó, Sara Puertas, María Martínez-Iniesta, Agnés Figueras, Laura Padullés, Francisco J. García-Rodriguez, Mireia Berdiel-Acer, Miguel A. Pujana, Ramón Salazar, Marta Gil-Martin, Lola Martí, Jordi Ponce, David G. Molleví, Gabriel Capella, Enric Condom, Francesc Viñals, Dori Huertas, Carmen Cuevas, Manel Esteller, Pablo Avilés, Alberto Villanueva
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5399–5411.
https://doi.org/10.1158/1078-0432.CCR-12-1513
Published: 30 September 2012
View article titled, Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
Open the PDF for Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Gene Expression Differences between Colon and Rectum Tumors

Rebeca Sanz-Pamplona, David Cordero, Antonio Berenguer, Flavio Lejbkowicz, Hedy Rennert, Ramon Salazar, Sebastiano Biondo, Xavier Sanjuan, Miguel A. Pujana, Laura Rozek, Thomas J. Giordano, Ofer Ben-Izhak, Hector I. Cohen, Philip Trougouboff, Jacob Bejhar, Yanina Sova, Gad Rennert, Stephen B. Gruber, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7303–7312.
https://doi.org/10.1158/1078-0432.CCR-11-1570
Published: 30 November 2011
View article titled, Gene Expression Differences between Colon and Rectum Tumors
Open the PDF for Gene Expression Differences between Colon and Rectum Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Gunnar Folprecht, Josep Tabernero, Claus-Henning Köhne, Charles Zacharchuk, Luis Paz-Ares, Federico Rojo, Susan Quinn, Esther Casado, Ramon Salazar, Richat Abbas, Chantal Lejeune, Irene Marimón, Jordi Andreu, Ulrike Ubbelohde, Hernan Cortes-Funes, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 215–223.
https://doi.org/10.1158/1078-0432.CCR-07-1053
Published: 02 January 2008
View article titled, Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Open the PDF for Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer in another window
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario, Sophia Campbell, Jay Zhi, Steve Ritland, Jim Cassidy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4374–4382.
https://doi.org/10.1158/1078-0432.CCR-04-0135
Published: 06 July 2004
View article titled, A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors in another window
Journal Articles

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Hans Gelderblom, Ramon Salazar, Jaap Verweij, George Pentheroudakis, Maja J. A. de Jonge, Martin Devlin, Christel van Hooije, Francis Seguy, Rosendo Obach, Joan Pruñonosa, Paola Principe, Chris Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4101–4107.
Published: 30 September 2003
View article titled, Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
Open the PDF for Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors in another window